New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Gilead announced Phase 2 PURPOSE 5 results showing twice-yearly injectable lenacapavir achieved 85.6% one-year PrEP persistence versus 46.3% for daily oral F/TDF (p<0.0001). Zero HIV acquisitions occurred among lenacapavir recipients over the 52-week study period, versus one acquisition in the F/TDF arm, with a safety profile consistent with prior studies.
Key figures
- Drug Name
- lenacapavir
- Phase Of Trial
- Phase 2
- P value
- p<0.0001
- Serious aes ftdf
- 3.4%
- Participants enrolled
- 267
- Ftdf persistence week52
- 46.3% (37/80)
- Serious aes lenacapavir
- 3.9%
- Hiv acquisitions ftdf arm
- 1
- Lenacapavir persistence week52
- 85.6% (154/180)
- Hiv acquisitions lenacapavir arm
- 0
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.